Afimmune Will Present Data on Oral DS102 at the European Respiratory Society

Afimmune announces DS102 will be developed for pulmonary disorders in addition to NASH
May 23, 2016
Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis
March 29, 2017
Show all

Afimmune Will Present Data on Oral DS102 at the European Respiratory Society

Dublin, Ireland, 6th September 2016: Afimmune will today present an abstract entitled ”DS102: a bioactive lipid for the treatment of chronic pulmonary disorders” at the European Respiratory Society in London, United Kingdom.

Afimmune is planning to initiate an Oral DS102 Phase IIa study in patients with Chronic Obstructive Pulmonary Disease (COPD) later this year. Separately, a Phase IIa study with Oral DS102 will also be conducted in patients with Non-Alcoholic Steatohepatitis (NASH).

About Afimmune
Afimmune Limited (Afimmune), headquartered in Dublin, Ireland, is a drug discovery company working on inflammatory conditions of the human primary organs including the liver and the lung. DS102 was recently spun out by DS Biopharma into Afimmune.

The abstract is available for a limited time at this link – http://erscongress.org/programme-2016/access-the-programme.html

Please search DS102 under ‘keywords’ and scroll down to the 12.30 session.
Contact:
info@afimmune.com